Insider Selling: Simulations Plus, Inc. (NASDAQ:SLP) Director Sells $1,114,260.29 in Stock

Simulations Plus, Inc. (NASDAQ:SLPGet Rating) Director Walter S. Woltosz sold 18,121 shares of Simulations Plus stock in a transaction dated Monday, August 29th. The shares were sold at an average price of $61.49, for a total value of $1,114,260.29. Following the sale, the director now owns 4,099,786 shares of the company’s stock, valued at $252,095,841.14. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Simulations Plus Stock Performance

Shares of SLP stock opened at $57.21 on Friday. The stock’s 50 day simple moving average is $58.96 and its 200 day simple moving average is $49.96. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of 103.13 and a beta of 0.42. Simulations Plus, Inc. has a twelve month low of $35.18 and a twelve month high of $67.59.

Simulations Plus (NASDAQ:SLPGet Rating) last issued its quarterly earnings results on Wednesday, July 6th. The technology company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.17 by $0.03. The company had revenue of $14.96 million for the quarter, compared to the consensus estimate of $14.33 million. Simulations Plus had a return on equity of 6.91% and a net margin of 22.74%. The company’s revenue for the quarter was up 17.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.18 EPS. On average, analysts forecast that Simulations Plus, Inc. will post 0.64 EPS for the current fiscal year.

Simulations Plus Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 1st. Stockholders of record on Monday, July 25th were issued a dividend of $0.06 per share. This represents a $0.24 annualized dividend and a dividend yield of 0.42%. The ex-dividend date of this dividend was Friday, July 22nd. Simulations Plus’s payout ratio is presently 42.11%.

Analyst Ratings Changes

SLP has been the subject of several research reports. Craig Hallum lifted their price target on Simulations Plus from $55.00 to $60.00 and gave the company a “buy” rating in a report on Thursday, July 7th. TheStreet raised Simulations Plus from a “c+” rating to a “b-” rating in a research note on Friday, July 22nd. Finally, Raymond James raised their price objective on Simulations Plus from $54.00 to $70.00 and gave the company an “outperform” rating in a research note on Monday, August 29th. Two investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, Simulations Plus has a consensus rating of “Moderate Buy” and a consensus price target of $65.00.

Institutional Trading of Simulations Plus

Institutional investors have recently modified their holdings of the company. Gotham Asset Management LLC acquired a new stake in shares of Simulations Plus during the 4th quarter worth approximately $225,000. Congress Asset Management Co. MA boosted its stake in Simulations Plus by 5.4% in the 1st quarter. Congress Asset Management Co. MA now owns 142,394 shares of the technology company’s stock valued at $7,259,000 after buying an additional 7,359 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in Simulations Plus in the 1st quarter valued at $32,000. Ranger Investment Management L.P. boosted its stake in Simulations Plus by 12.3% in the 4th quarter. Ranger Investment Management L.P. now owns 882,164 shares of the technology company’s stock valued at $41,726,000 after buying an additional 96,272 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Simulations Plus by 96.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 80,316 shares of the technology company’s stock valued at $3,799,000 after buying an additional 39,472 shares in the last quarter. Institutional investors and hedge funds own 72.51% of the company’s stock.

About Simulations Plus

(Get Rating)

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft.

Read More

Insider Buying and Selling by Quarter for Simulations Plus (NASDAQ:SLP)

Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.